Protagonist Therapeutics Inc (PTGX)

Currency in USD
53.87
-0.03(-0.06%)
Closed·
After Hours
53.870.00(0.00%)
·
PTGX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
PTGX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
52.1154.37
52 wk Range
33.3160.60
Key Statistics
Prev. Close
53.87
Open
53.42
Day's Range
52.11-54.37
52 wk Range
33.31-60.6
Volume
449.17K
Average Volume (3m)
827.01K
1-Year Change
48.77%
Book Value / Share
11.23
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PTGX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
69.00
Upside
+28.09%
Members' Sentiments
Bearish
Bullish
ProTips
4 analysts have revised their earnings downwards for the upcoming period
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

Protagonist Therapeutics Inc Company Profile

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Protagonist Therapeutics Inc SWOT Analysis


Promising Pipeline
Protagonist's rusfertide and icotrokinra show potential in polycythemia vera and inflammatory bowel diseases, with projected peak sales in billions
Financial Strength
$698M cash reserves provide runway through 2028, supporting aggressive development of early-stage assets despite current operating losses
Competitive Edge
PN-881, a highly potent IL-17 antagonist, could revolutionize psoriasis treatment, potentially outperforming existing antibody-based therapies
Market Outlook
Analysts set price targets ranging from $50 to $80, reflecting optimism about Protagonist's pipeline and market potential in multiple therapeutic areas
Read full SWOT analysis

Compare PTGX to Peers and Sector

Metrics to compare
PTGX
Peers
Sector
Relationship
P/E Ratio
59.4x−1.7x−0.5x
PEG Ratio
−0.87−0.070.00
Price/Book
4.8x2.2x2.6x
Price / LTM Sales
16.1x38.1x3.3x
Upside (Analyst Target)
29.9%303.2%43.5%
Fair Value Upside
Unlock20.0%6.9%Unlock

Analyst Ratings

10 Buy
1 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 69.00
(+28.09% Upside)

Earnings

Latest Release
Aug 06, 2025
EPS / Forecast
-0.55 / -0.58
Revenue / Forecast
5.55M / 7.51M
EPS Revisions
Last 90 days

PTGX Income Statement

People Also Watch

263.10
AVAV
-0.62%
232.39
LEU
+8.70%
117.34
CRDO
+6.39%
37.71
EXEL
+0.67%
45.930
SMR
+1.77%

FAQ

What Stock Exchange Does Protagonist Therapeutics Trade On?

Protagonist Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Protagonist Therapeutics?

The stock symbol for Protagonist Therapeutics is "PTGX."

What Is the Protagonist Therapeutics Market Cap?

As of today, Protagonist Therapeutics market cap is 3.34B.

What Is Protagonist Therapeutics's Earnings Per Share (TTM)?

The Protagonist Therapeutics EPS (TTM) is 0.91.

When Is the Next Protagonist Therapeutics Earnings Date?

Protagonist Therapeutics will release its next earnings report on 04 Nov 2025.

From a Technical Analysis Perspective, Is PTGX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Protagonist Therapeutics Stock Split?

Protagonist Therapeutics has split 0 times.

How Many Employees Does Protagonist Therapeutics Have?

Protagonist Therapeutics has 124 employees.

What is the current trading status of Protagonist Therapeutics (PTGX)?

As of 07 Aug 2025, Protagonist Therapeutics (PTGX) is trading at a price of 53.87, with a previous close of 53.87. The stock has fluctuated within a day range of 52.11 to 54.37, while its 52-week range spans from 33.31 to 60.60.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.